Gopa Iyer, MD, on LY4052031 for Advanced or Metastatic Urothelial Carcinoma

June 05, 2026

Gopa Iyer, MD, of Memorial Sloan Kettering Cancer Center, presents initial results from the phase I NEXUS-01 study, which evaluated LY4052031, an antibody-drug conjugate targeting Nectin-4, in patients with advanced or metastatic urothelial carcinoma (Abstract 4508). 

Related Content